Stocks in play: Antibe Therapeutics Inc

Announced the appointment of Robert E. Hoffman and Jennifer McNealey to its Board of Directors. “We are delighted to welcome Jennifer and Robert to our team,” said Walt Macnee, Chair of Antibe’s Board of Directors. Until his retirement last month, Mr. Hoffman was Chief Financial Officer of San Diego-based Heron Pharmaceuticals, a NASDAQ-listed commercial stage drug developer with a pipeline of acute pain therapeutics. Ms. McNealey is a senior financial and strategy executive with a considerable breadth of experience in the biotechnology sector, as an analyst, portfolio manager, information provider and expert in corporate communications and investor relations. She is currently Vice President, Investor Relations and Strategy for South San Francisco-based Calithera Biosciences. “Both are highly accomplished biotechnology executives, with significant experience in U.S. capital markets, public company governance and financial operations – all of which will be invaluable to Antibe as we move toward a potential listing on a senior U.S. exchange in parallel with large market partnering efforts.” Antibe Therapeutics Inc shares T.ATE are trading up 3.95 percent at $0.40.

Read:

• These Are Some of the Best Ways to Gain Exposure to the Booming eSports Market

• The Investment Trend That Could Send Tesla To $2 Trillion